Abstract: The present invention is generally related to an agricultural formulation comprising 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydroinden-4-yl]pyrazole-4-carboxamide and sodium salt of naphthalene sulfonate condensate and polyoxyethylene tristyrylphenol phosphate, potassium salt. The present invention is further related to an agricultural formulation comprising 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydroinden-4-yl]pyrazole-4-carboxamide, ethaboxam, metalaxyl, mandestrobin, methyloxirane polymer, sodium salt of naphthalene sulfonate condensate, a mixture of sodium salt of alkyl vinyl ether/maleic acid half-ester copolymer and polyvinyl pyrrolidone and polyoxyethylene tristyrylphenol phosphate, potassium salt. The present invention is further directed to a process for preparing the agricultural formulations and methods of use thereof.

Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of one or more of Butyrospermum parkii (shea butter), PEG-50 shea butter, glycerin, Helianthus annuus (sunflower) seed oil, Prunus armeniaca (apricot) kernel oil, acrylates copolymer, sodium lauryl sulfate, lauramidopropyl betaine, sodium methyl cocoyl taurate, glycerin, and polyquaternium-7.

Abstract: Fungal diseases and resulting mycotoxins are reduced or eliminated from plant tissues during crop growth or post-harvest during storage by treatment with an aqueous spray solution prepared from a fungicide composition of a bicarbonate salt containing a surfactant system to reduce the surface tension and contact angle of the spray solution on the plant surface thereby controlling the crystal size of the bicarbonate and re-distribution and adherence of the crystals to the crop vegetation and/or grains.

Abstract: Aminofunctional silicone emulsions are prepared by forming a mixture of A) 100 parts of a polydialkylsiloxane Having a viscosity of at least 50,000 mm/s at 23° C., and B) 0.1 to 100 parts of an aminofunctional organopolysiloxane, admixing C) 0.1 to 50 parts of a halide free quaternary ammonium surfactant containing at least 10 carbon atoms, and a sufficient amount of water to form an emulsion.

Abstract: The present invention provides a cosmetic composition comprising, in a cosmetically acceptable organic liquid medium, at least one film-forming ethylenic linear block polymer, and another film former. The film former may be soluble or dispersible in the said organic liquid medium. The composition may include an aqueous phase, in which case the film former may be soluble or dispersible in the aqueous phase. The invention further provides for the use of the combination of such a block polymer and a film former for enhancing the staying power of the said composition on the keratin materials.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: Composition for topical application in the form of an oil-in-water emulsion containing an oily phase dispersed in an aqueous phase, and a hydrophilic polymer, the composition further containing (1) at least one elastomeric organopolysiloxane and (2) at least one lipophilic compound chosen from lipophilic amino acid compounds and lipophilic salicylic acid compounds. Uses thereof, including topical application to the skin, lips, hair, etc. Stabilization of certain emulsions using a lipophilic compound.

Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.

Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.

Abstract: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.

Abstract: The present invention provides lipid emulsions and methods of intravenously administering lipid emulsions to treat systemic toxicity caused by foreign lipophilic and amphiphilic substances. In particular, methods are provided to treat cardiovascular impairment, such as cardiotoxicity, asystole and ischemia of the brain and heart, and neurological impairments, such as seizures and comas, caused by foreign lipophilic and amphiphilic substances, including cardiovascular impairment caused by local anesthetics, tricyclic antidepressants, sodium channel blockers, and calcium channel blockers.

Abstract: The present invention provides a formulation comprising a pesticide and/or a plant growth regulator; an acyl morpholine of the formula (I) where R is H, CH3 or C2H5; and a polar aprotic co-solvent different from an acyl morpholine of formula (I). The formulation can be used in treatment of plants, and is especially well suited for use as a soluble liquid formulation.

Abstract: The present invention provides a nano-micellar preparation containing vinca alkaloids antitumor agent for intravenous injection, which cincludes a therapeutically effective amount of vinca alkaloids antitumor agent (vinblastine, vincristine, vindesine and vinorelbine), a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation containing vinca alkaloids antitumor agent for injection. The vinca alkaloids antitumor agent and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly uniform particle size.

Abstract: The present invention relates to a perfluorocarbon nanoemulsion containing quantum dot nanoparticles and a method for preparing the same, more specifically, relates to a method for preparing a multifunctional perfluorocarbon nanoemulsion which simultaneously shows the fluorine-based magnetic resonance properties of perfluorocarbon and the optical properties of quantum dot nanoparticles, the method comprising dispersing quantum dot nanoparticles, modified with a fluorine end group, in perfluorocarbon, and then adding an aqueous emulsifier solution containing lipid to the dispersion. The disclosed perfluorocarbon nanoemulsion containing quantum dot nanoparticles has excellent biocompatibility and simultaneously shows optical properties and magnetic resonance properties, and thus can be used as a contrast agent for multi-mode molecular imaging. Accordingly, the nanoemulsion can be used to study cell and small-animal molecular imaging in various fields, including biological and medical fields.

Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.

Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.

Abstract: Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: The present invention pertains to oil-in-water emulsion compositions having hydrophobic materials stably dispersed therein and methods for making such. The preferred method of making the emulsion compositions the formation of two O/W emulsions. A first O/W emulsion is for wetting or otherwise pre-treating the hydrophobic components. Thereafter, the first emulsion is added to a second O/W emulsion after the second emulsion has been formed. Both emulsions use a ternary surfactant blend of cationic, anionic and bridging surfactants, making the finished product a double or “binary-CAN” emulsion system. Generally, the system has a bi-modal oil droplet distribution.

Abstract: Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents.

Abstract: A heavy oil cleaning composition comprising: a) a blend of dibasic esters comprising dialkyl methylglutarate and at least one of a dialkyl adipate or dialkyl ethylsuccinate; b) at least one terpene; and c) at least one surfactant. Also described are methods for delivering a solvent at reduced concentration comprising the steps of: a) obtaining a terpene-based solvent; and b) mixing the terpene-based solvent with a carrier fluid (the carrier fluid comprising a microemulsion of i) a blend of dibasic esters selected from the group consisting of dialkyl methylglutarate, dialkyl adipate, dialkyl ethylsuccinate, dialkyl succinate, dialkyl glutarate and any combination thereof, ii) at least one surfactant selected from the group consisting of a terpene alkoxylate, an alcohol alkoxylate and any combination thereof; and iii) water) in order to obtain a mixture to clean heavy oils.

Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.

Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Abstract: A cosmetic composition comprising a first emulsion and a second emulsion and optionally one or more additional emulsions, each of the two or more emulsions being discretely contained within the composition and comprising an inner phase and an outer phase, each of the two or more emulsions being independently a water-in-oil emulsion, an oil-in-water emulsion, an oil-in-oil emulsion, a polyol-in-oil emulsion, a water-in-silicone emulsion, a silicone-in-water emulsion, or a polyol-in-silicone emulsion in physical contact with at least one other emulsion, at least one of the two or more emulsions being visually distinct from the others, and each of the two or more emulsions as well as the composition being independently both physically and visually stable within the composition for at least six months at ambient temperature.

Abstract: Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.

Abstract: A gelled cleaning composition is provided that includes a standard temperature and pressure (STP) liquid oil or STP malleable wax present from 0.1 to 9.9 total weight percent. An emulsifier is present from 0.01 to 10 total weight percent, along with an alkylene glycol present from 0.002 to 11 total weight percent. A microemulsion is present in the composition from 0.2 to 15 total weight percent. Water forms a majority of the composition such that the composition is monophasic for at least 4 months storage at 20° Celsius. The composition is well suited for use in a process to remove a lipophilic substance from hands or an inanimate substrate by applying the composition and after allow sufficient time for the substance to be softened or solubilized, removing the composition and at least a portion of the substance. Silicone gaskets, as well as other cured resins and paints are readily removed.

Abstract: The present invention is directed to a lamellar oil-in-glycol gel comprising (a) at least one glycol, (b) at least one fatty alcohol, (c) at least one cationic surfactant and optionally (d) at least one benefit agent, said lamellar gel capable of providing enhanced mass and promoting the permeation of the benefit agent through a keratinous substrate such as the skin, hair and fingernails, providing both deep and superficial treatment thereof.

Abstract: Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier.

Abstract: Polyamide-5 compounds show an increase of the care and/or efficacy properties of cosmetic or dermatological preparations, such as waterproofness, long-term stability, skin moisture and stickiness. The preparations preferably comprise one or more care agents or active ingredients selected from the group of UV filter substances, anti-wrinkle active ingredients, skin moisturizers and/or lipids.

Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.

Abstract: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

Abstract: Aqueous compositions including a discontinuous oil phase containing an ultraviolet radiation-absorbing polymer stabilized in a continuous aqueous phase, an oil-gelling polymer, and which are substantially free of non-polymeric ultraviolet radiation-absorbers.

Abstract: A one-phase microemulsion composition, which can be easily prepared without the use of special equipment, has high safety, and stays stable for a long period in an ultrafine emulsion state when the composition is added to an aqueous formulation, is provided by appropriately adjusting the ratio of (A) a hydrophilic nonionic surfactant, (B) a lipophilic nonionic surfactant, (C) an oil component, (D) a water-miscible solvent that does not interdissolve with the oil component, and the critical micelle concentration (CMC) of the hydrophilic nonionic surfactant in the water-miscible solvent is higher than that of the hydrophilic nonionic surfactant in water, and (E) water.

Abstract: Drugs which are difficult to solubilize in water, and especially those which otherwise cause pain on injection, can be readily formulated and typically administered with substantially less pain when solubilized in synergistic, aqueous micellar preparations of poloxamers. Such preparations may also be prepared with less, or without, co-solvents.

Abstract: An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.

Abstract: This disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.

Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Abstract: A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising H2O; (ii) an oil phase comprising oil dispersed in the continuous aqueous phase, comprising an internal aqueous phase comprising H2O, being dispersed in the oil phase; and a physiologically acceptable lipophilic emulsifier selected from the group consisting of mannide monooleate and sorbitan esters, stabilizing the interface between the inner aqueous phase and the oil phase to form a water-in-oil (W/O) emulsion; and (iii) poly(ethylene glycol)-block-poly(lactide-co-?-caprolactone), stabilizing the interface between the oil phase and the continuous aqueous phase.

Abstract: A solubilizing composition containing (A) at least one oily component selected from esters of oleic acid with alcohols having 1 to 3 carbon atoms and triglycerides of fatty acids having 6 to 12 carbon atoms, (B) a polyoxyethylenesorbitan fatty acid ester, (C) a polyhydric alcohol which is liquid between 15° C. and 25° C., and (D) one or more acidic phospholipids where the fatty acid constituting an acyl group thereof is selected from saturated fatty acids having 6 to 14 carbon atoms and unsaturated fatty acids having 16 to 18 carbon atoms, which contains 20 to 40% by weight of the component (A), 30 to 45% by weight of the component (B), 15 to 40% by weight of the component (C), and 0.5 to 4% by weight of the component (D), based on 100% by weight of a total amount of the components (A) to (D).

Abstract: Provided is an O/W emulsion cosmetic composition, which contains the following components (A), (B) and (C): (A) a polymer which is either a nonionic or cationic polymer composed of a hydrophobic monomer unit and a hydrophilic monomer unit and contains from 40 to 80 wt. % of a hydrophilic group; (B) a dispersion containing the following components (a), (b), (c) and (d): (a) powders having ultraviolet screening ability and having a surface subjected to hydrophobic treatment, (b) a polymer composed of a hydrophobic monomer unit and a hydrophilic monomer unit, (c) a silicone oil, and (d) an alcohol having from 1 to 3 carbon atoms, at an (a):(b):(c):(d) weight ratio of (from 25 to 65):(from 0.1 to 5):(from 10 to 50):(from 10 to 50); and (C) water.

Abstract: The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: The invention pertains to a new method for formulating any agrochemical active ingredient so as to protect the user, protect this active ingredient from outside stresses, and control its release kinetics. It relies on the use of acrylic and thickening emulsions with a pH greater than five and containing hydrophobic groups in order to trap said active ingredient. The invention also pertains to the various embodiments of the active ingredient thereby formulated: a mixture in water of that active ingredient with these thickening emotions, a dispersion of solid particles of these polymers and this active ingredient after a certification, and the solid particles obtained in a dried state after the water has been removed. Finally, the invention pertains to the use of these various formulations in order to protect and active ingredient, protect its user, and slow its release kinetics.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: A fat emulsion comprises a prostaglandin as an active ingredient, the fat emulsion comprising a phospholipid that comprises phosphatidylcholine (PC) and phosphatidylglycerol (PG) and has a ratio of PC to PG (PC:PG) of 85:15 to 99.7:0.3.

Abstract: An stable oil-in-oil emulsion is disclosed containing a first oil phase dispersed as droplets in a continuous second oil phase, which droplets have a number median diameter of 10 nm to 1000 nm, wherein the first oil phase is substantially immiscible in the second oil phase and wherein the first oil phase comprises a liquid organic phosphate compound. In one preferred embodiment, the first oil phase comprises colorants, polymers, and/or other additives, depending on the particular use of the emulsion.

Abstract: A pharmaceutical compositions in the form of an emulsion and containing a continuous liquid phase, for example, an aqueous phase, liquid droplets dispersed in the continuous phase, a pharmaceutically active compound, a Hseih enhancer, and a hydrocolloid emulsifying agent and in which, for example, the active compound is dissolved in the aqueous phase or in the liquid droplets, and the use of such composition to treat a condition in a patient, for example, diabetes.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.